Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.38 |
| ▸ | PPARG | P37231 | 2/20 | 0.35 |
| ▸ | MAOA | P21397 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | CA9 | Q16790 | 1/20 | 0.31 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10024051 | 1.00 | SMN1; SMN2 (0.44) | SMN1; SMN2CYP1A2PPARGMAOACA1 | |
| SCHEMBL16090895 | 1.00 | SMN1; SMN2 (0.44) | SMN1; SMN2CYP1A2PPARGMAOACA1 | |
| SCHEMBL14392849 | 1.00 | SMN1; SMN2 (0.44) | SMN1; SMN2CYP1A2PPARGMAOACA1 | |
| SCHEMBL14520416 | 0.84 | CYP1A2 (0.43) | SMN1; SMN2CYP1A2PPARGSIRT2 | |
| SCHEMBL12732035 | 0.84 | CYP1A2 (0.43) | SMN1; SMN2CYP1A2PPARGSIRT2 | |
| SCHEMBL11955423 | 0.82 | SMN1; SMN2 (0.43) | SMN1; SMN2CYP1A2PPARGCA1CA9 | |
| SCHEMBL12897962 | 0.82 | SMN1; SMN2 (0.43) | SMN1; SMN2CYP1A2PPARG | |
| SCHEMBL14520404 | 0.82 | SMN1; SMN2 (0.43) | SMN1; SMN2CYP1A2PPARG | |
| SCHEMBL26383054 | 0.80 | SMN1; SMN2 (0.48) | SMN1; SMN2CYP1A2PPARGMAOACA1 | |
| SCHEMBL9300447 | 0.80 | SMN1; SMN2 (0.48) | SMN1; SMN2CYP1A2PPARGMAOACA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8148550-B2 | selected from fluvastatin, rosuvastatin, cerivastatin, glenvastatin or atorvastatin, by reduction or lactonization of chemical intermediate compounds, then hydrogenation, decyclization and deprotection of hydroxy groups | RATIOPHARM GMBH (DE) | 2012-04-03 | — | — | US | disclosed |
| US-20080249306-A1 | Method for the Production of Statins | RATIOPHARM GMBH (DE) | 2008-10-09 | — | — | US | disclosed |
| US-20070093660-A1 | Method for the production of statins | RATIOPHARM GMBH (DE) | 2007-04-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070093660-A1 | Method for the production of statins | HMGCR, CYP11A1, CYP51A1 | SMN1; SMN2 3988/4885CYP1A2 69/4885PPARG 2957/4885 |
| US-20080249306-A1 | Method for the Production of Statins | HMGCR, COASY, PCSK9 | SMN1; SMN2 4803/4885CYP1A2 190/4885PPARG 1376/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.